Related references
Note: Only part of the references are listed.Bullous pemphigoid induced by ustekinumab: a case report
Marta Marin et al.
EUROPEAN JOURNAL OF HOSPITAL PHARMACY (2021)
Milestones in Personalized Medicine in Pemphigus and Pemphigoid
Katja Bieber et al.
FRONTIERS IN IMMUNOLOGY (2021)
Rituximab versus Mycophenolate Mofetil in Patients with Pemphigus Vulgaris
V. P. Werth et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Mepolizumab failed to affect bullous pemphigoid: A randomized, placebo-controlled, double-blind phase 2 pilot study
Dagmar Simon et al.
ALLERGY (2020)
A new ex vivo human oral mucosa model reveals that p38MAPK inhibition is not effective in preventing autoantibody-induced mucosal blistering in pemphigus
D. T. Egu et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect
D. M. Chen et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Autoreactive B Cell Differentiation in Diffuse Ectopic Lymphoid-Like Structures of Inflamed Pemphigus Lesions
Shengru Zhou et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2020)
Clinical outcome and safety of rituximab therapy for pemphigoid diseases
Napatra Tovanabutra et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Comparison of C3d immunohistochemical staining to enzyme-linked immunosorbent assay and immunofluorescence for diagnosis of bullous pemphigoid
Leo L. Wang et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Recent Advances in Understanding Pemphigus and Bullous Pemphigoid
Christoph M. Hammers et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2020)
Dupilumab as a novel therapy for bullous pemphigoid: A multicenter case series
Rana Abdat et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris
Jinmin Lee et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
IL-17A is functionally relevant and a potential therapeutic target in bullous pemphigoid
Lenche Chakievska et al.
JOURNAL OF AUTOIMMUNITY (2019)
Rituximab therapy in patients with bullous pemphigoid: A retrospective study of 20 patients
Maxim Polansky et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Walnut antigens can trigger autoantibody development in patients with pemphigus vulgaris through a hit-and-run mechanism
Lan Lin et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2019)
Single-Cell Analysis Suggests that Ongoing Affinity Maturation Drives the Emergence of Pemphigus Vulgaris Autoimmune Disease
Alice Cho et al.
CELL REPORTS (2019)
Complement Activation in Autoimmune Bullous Dermatoses: A Comprehensive Review
Gareth Edwards et al.
FRONTIERS IN IMMUNOLOGY (2019)
Factors Associated With Complete Remission After Rituximab Therapy for Pemphigus
Carolyn J. Kushner et al.
JAMA DERMATOLOGY (2019)
The Intersection of IgE Autoantibodies and Eosinophilia in the Pathogenesis of Bullous Pemphigoid
Kelly N. Messingham et al.
FRONTIERS IN IMMUNOLOGY (2019)
C1s Inhibition by BIVV009 (Sutimlimab) Prevents Complement-Enhanced Activation of Autoimmune Human B Cells In Vitro
Pavel A. Nikitin et al.
JOURNAL OF IMMUNOLOGY (2019)
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex-mediated immune responses
L. J. Blumberg et al.
SCIENCE ADVANCES (2019)
B-cell depletion induces a shift in self antigen specific B-cell repertoire and cytokine pattern in patients with bullous pemphigoid
Berkani Nicolas et al.
SCIENTIFIC REPORTS (2019)
Mechanisms Causing Loss of Keratinocyte Cohesion in Pemphigus
Volker Spindler et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2018)
The Anti-C1s Antibody TNT003 Prevents Complement Activation in the Skin Induced by Bullous Pemphigoid Autoantibodies
Anika Kasprick et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Autoantibody Signaling in Pemphigus vulgaris: Development of an integrated Model
Thomas Sajda et al.
FRONTIERS IN IMMUNOLOGY (2018)
Tissue Destruction in Bullous Pemphigoid Can Be Complement Independent and May Be Mitigated by C5aR2
Christian M. Karsten et al.
FRONTIERS IN IMMUNOLOGY (2018)
Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans
Peter Ulrichts et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Autoreactive IgG and IgA B Cells Evolve through Distinct Subclass Switch Pathways in the Autoimmune Disease Pemphigus Vulgaris
Christoph T. Ellebrecht et al.
CELL REPORTS (2018)
A successful treatment with ustekinumab in a case of relapsing bullous pemphigoid associated with psoriasis
J. Loget et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2017)
IgG4, complement, and the mechanisms of blister formation in pemphigus and bullous pemphigoid
Teruki Dainichi et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2017)
Non-pathogenic pemphigus foliaceus (PF) IgG acts synergistically with a directly pathogenic PF IgG to increase blistering by p38MAPK-dependent desmoglein 1 clustering
Kenji Yoshida et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2017)
First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial
Pascal Joly et al.
LANCET (2017)
Blockade of HLA Antibody-Triggered Classical Complement Activation in Sera From Subjects Dosed With the Anti-C1s Monoclonal Antibody TNT009-Results from a Randomized First-in-Human Phase 1 Trial
Jakob Muehlbacher et al.
TRANSPLANTATION (2017)
Proteomic Analysis of Pemphigus Autoantibodies Indicates a Larger, More Diverse, and More Dynamic Repertoire than Determined by B Cell Genetics
Jing Chen et al.
CELL REPORTS (2017)
Pemphigus
Michael Kasperkiewicz et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
Stat3 regulates desmoglein 3 transcription in epithelial keratinocytes
Xuming Mao et al.
JCI INSIGHT (2017)
The Reliability, Validity and Responsiveness of Two Disease Scores (BPDAI and ABSIS) for Bullous Pemphigoid: Which One to Use?
Asri Wijayanti et al.
ACTA DERMATO-VENEREOLOGICA (2017)
Mechanisms of Disease: Pemphigus and Bullous Pemphigoid
Christoph M. Hammers et al.
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 11 (2016)
Determinants of VH1-46 Cross-Reactivity to Pemphigus Vulgaris Autoantigen Desmoglein 3 and Rotavirus Antigen VP6
Michael Jeffrey Cho et al.
JOURNAL OF IMMUNOLOGY (2016)
Combined integrated protocol/basket trial design for a first-in-human trial
Ulla Derhaschnig et al.
ORPHANET JOURNAL OF RARE DISEASES (2016)
Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease
Christoph T. Ellebrecht et al.
SCIENCE (2016)
First-line combination therapy with rituximab and corticosteroids provides a high complete remission rate in moderate-to-severe bullous pemphigoid
Y. T. Cho et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
Development of bullous pemphigoid during treatment of psoriatic onycho-pachydermo periostitis with ustekinumab
Chihiro Nakayama et al.
JOURNAL OF DERMATOLOGY (2015)
Persistence of Anti-Desmoglein 3 IgG+ B-Cell Clones in Pemphigus Patients over Years
Christoph M. Hammers et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2015)
Desmosomal Cadherins and Signaling: Lessons from Autoimmune Disease
Volker Spindler et al.
CELL COMMUNICATION AND ADHESION (2014)
MAPKAP Kinase 2 (MK2)-Dependent and -Independent Models of Blister Formation in Pemphigus Vulgaris
Xuming Mao et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2014)
Innate Immune Cell-Produced IL-17 Sustains Inflammation in Bullous Pemphigoid
Sebastien Le Jan et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2014)
Omalizumab therapy for bullous pemphigoid
Kenneth K. Yu et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2014)
Shared VH1-46 gene usage by pemphigus vulgaris autoantibodies indicates common humoral immune responses among patients
Michael Jeffrey Cho et al.
NATURE COMMUNICATIONS (2014)
A higher correlation of the antibody activities against the calcium-dependent epitopes of desmoglein 3 quantified by ethylenediaminetetraacetic acid-treated enzyme-linked immunosorbent assay with clinical disease activities of pemphigus vulgaris
Koji Kamiya et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2013)
Association of Serum B-Cell Activating Factor Level and Proportion of Memory and Transitional B Cells with Clinical Response after Rituximab Treatment of Bullous Pemphigoid Patients
Russell P. Hall et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2013)
B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies
Maria J. Leandro
ARTHRITIS RESEARCH & THERAPY (2013)
Enrichment of total serum IgG4 in patients with pemphigus
T. Funakoshi et al.
BRITISH JOURNAL OF DERMATOLOGY (2012)
Inhibitory human antichimeric antibodies to rituximab in a patient with pemphigus
Luisa Lunardon et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2012)
Pemphigus autoantibodies generated through somatic mutations target the desmoglein-3 cis-interface
Giovanni Di Zenzo et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Cutting Edge: Brazilian Pemphigus Foliaceus Anti-Desmoglein 1 Autoantibodies Cross-React with Sand Fly Salivary LJM11 Antigen
Ye Qian et al.
JOURNAL OF IMMUNOLOGY (2012)
Epitope Spreading Is Rarely Found in Pemphigus Vulgaris by Large-Scale Longitudinal Study Using Desmoglein 2-Based Swapped Molecules
Bungo Ohyama et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2012)
Signaling Dependent and Independent Mechanisms in Pemphigus Vulgaris Blister Formation
Masataka Saito et al.
PLOS ONE (2012)
Blockade of Autoantibody-Initiated Tissue Damage by Using Recombinant Fab Antibody Fragments against Pathogenic Autoantigen
Gang Wang et al.
AMERICAN JOURNAL OF PATHOLOGY (2010)
Immune response towards the amino-terminus of desmoglein 1 prevails across different activity stages in nonendemic pemphigus foliaceus
P. T. Chan et al.
BRITISH JOURNAL OF DERMATOLOGY (2010)
Novel ELISA systems for antibodies to desmoglein 1 and 3: correlation of disease activity with serum autoantibody levels in individual pemphigus patients
Enno Schmidt et al.
EXPERIMENTAL DERMATOLOGY (2010)
Human IgG1 Monoclonal Antibody against Human Collagen 17 Noncollagenous 16A Domain Induces Blisters via Complement Activation in Experimental Bullous Pemphigoid Model
Qiang Li et al.
JOURNAL OF IMMUNOLOGY (2010)
Antibodies to the Desmoglein 1 Precursor Proprotein but Not to the Mature Cell Surface Protein Cloned from Individuals without Pemphigus
Jun Yamagami et al.
JOURNAL OF IMMUNOLOGY (2009)
Antigen Selection of Anti-DSG1 Autoantibodies During and Before the Onset of Endemic Pemphigus Foliaceus
Ye Qian et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2009)
A randomized double-blind trial of intravenous immunoglobulin for pemphigus
Masayuki Amagai et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2009)
Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid
Giovanni Di Zenzo et al.
CLINICAL IMMUNOLOGY (2008)
Isolation of pathogenic monoclonal anti-desmoglein 1 human antibodies by phage display of pemphigus foliaceus autoantibodies
Ken Ishii et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2008)
B-Cell Depletion Immunotherapy in Pemphigus: Effects on Cellular and Humoral Immune Responses
Hugo Mouquet et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2008)
Synergistic pathogenic effects of combined mouse monoclonal anti-desmoglein 3 IgG antibodies on pemphipus vulgaris blister formation
Hiroshi Kawasaki et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2006)
p38MAPK inhibition prevents disease in pemphigus vulgaris mice
Paula Berkowitz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Pathogenic human monoclonal antibody against desmoglein 3
Shih-Wei Yeh et al.
CLINICAL IMMUNOLOGY (2006)
Enzyme-linked immunosorbent assay using bacterial recombinant proteins of human BP230 as a diagnostic tool for bullous pemphigoid
M Yoshida et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2006)
Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases
N Li et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Pemphigus vulgaris IgG and methylprednisolone exhibit reciprocal effects on keratinocytes
VT Nguyen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Induction of pemphigus phenotype by a mouse monoclonal antibody against the amino-terminal adhesive interface of desmoglein 3
K Tsunoda et al.
JOURNAL OF IMMUNOLOGY (2003)
Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma
WK Weng et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Production of non-pathogenic human monoclonal antibodies to desmoglein 3 from pemphigus vulgaris patient
KC Bhol et al.
AUTOIMMUNITY (2002)
Skin-homing interleukin-4 and-13-producing cells contribute to bullous pemphigoid: Remission of disease is associated with increased frequency of interleukin-10-producing cells
Y Teraki et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2001)
Predominant IgG4 subclass in autoantibodies of pemphigus vulgaris and foliaceus
Y Futei et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2001)
A critical role for neutrophil elastase in experimental bullous pemphigoid
Z Liu et al.
JOURNAL OF CLINICAL INVESTIGATION (2000)
Share Paper
